CommentaryCatechol-O-methyltransferase inhibitors for treatment of Parkinson's disease
References (13)
- et al.
Tolcapone, bromocriptine, and Parkinson's disease
Lancet
(1997) - et al.
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly
Clin Pharmacol Ther
(1997) - et al.
Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
Neurology
(1994) - et al.
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
J Neurol Neurosurg Psychiatry
(1996) - et al.
Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors
Prog Drug Res
(1992) - RA Hauser ES Molho H Shale et al A pilot evalution of the tolerability, safety, and efficacy of tolcapone alone and in...
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 1998 Elsevier Ltd. All rights reserved.